


FORM PTO-1390 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE (REV. 1094)		ATTORNEY'S DOCKET NUMBER K0448/7007
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 09/7700817
INTERNATIONAL APPLICATION NO. PCT/JP99/02546	INTERNATIONAL FILING DATE 17 May 1999 (17.05.99)	PRIORITY DATE CLAIMED 19 May 1998 (19.05.98)
TITLE OF INVENTION SOLID PREPARATIONS FOR ORAL ADMINISTRATION OF GENE-RELATED DRUGS		
APPLICANT(S) FOR DO/EO/US TANIDA, Norifumi; GOTO, Takeshi; AOKI, Jun		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<p>1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.</p> <p>2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.</p> <p>3. <input checked="" type="checkbox"/> This express request to begin national procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).</p> <p>4. <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.</p> <p>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)).</p> <p>a. <input checked="" type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau).</p> <p>b. <input type="checkbox"/> has been transmitted by the International Bureau.</p> <p>c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</p> <p>6. <input checked="" type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)) with verification of translation.</p> <p><input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)).</p> <p>a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau).</p> <p>b. <input type="checkbox"/> have been transmitted by the International Bureau.</p> <p>c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</p> <p>d. <input checked="" type="checkbox"/> have not been made and will not be made.</p> <p>8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</p> <p>9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(C)(4)).</p> <p>10. <input checked="" type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(C)(5)).</p> <p>Items 11. To 16. Below concern document(s) or information included:</p> <p>11. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98 with references.</p> <p>12. <input checked="" type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</p> <p>13. <input checked="" type="checkbox"/> A FIRST preliminary amendment.</p> <p><input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.</p> <p>14. <input type="checkbox"/> A substitute specification (submitted as a first Preliminary Amendment).</p> <p>15. <input type="checkbox"/> A change of power of attorney and/or address letter.</p> <p>16. <input checked="" type="checkbox"/> Other items or information:</p> <p>Copy of International Application w/ sworn English translation</p> <p>Copy of Amendments on Claims under Article 34 w/ sworn English translation</p> <p>Copy of Written Opinion w/ sworn English translation</p> <p>Copy of International Preliminary Examination w/ sworn English translation</p> <p>Copy of International Application with International Search w/ English translation of search report</p> <p>Copy of PCT/IB/301,304,306,308,332</p>		
Express Mail Label No. EL310414345US Mailed November 20, 2000		

U.S. APPLICATION NO (If known, see 37 CFR 1.53) 09/700817		INTERNATIONAL APPLICATION PCT/JP99/02546		ATTORNEY'S DOCKET NUMBER K0448/7007	
17. <input checked="" type="checkbox"/> The following fees are submitted:				CALCULATIONS <small>PTO USE ONLY</small>	
BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5)):					
Search Report has been prepared by the EPO or JPO \$860.00					
International preliminary examination fee paid to USPTO (37 CFR 1.482) \$690.00					
No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)).. \$710.00					
Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO..... \$1000.00					
International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4) \$100.00					
ENTER APPROPRIATE BASIC FEE AMOUNT =				\$860.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 X 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total Claims	24- 20 =	4	X \$18.00	\$ 72.00	
Independent Claims	1- 3 =	0	X \$80.00	\$	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$270.00	\$270.00	
TOTAL OF ABOVE CALCULATIONS =				\$	
Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).				\$	
SUBTOTAL =				\$	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$	
TOTAL NATIONAL FEE =				\$	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate coversheet (37 CFR 3.28, 3.31). \$40.00 per property +				\$ 40.00	
TOTAL FEES ENCLOSED =				\$	
				Amount to be: refunded \$	
				charged \$	
<p>a. A check in the amount of \$_____ to cover the above fees is enclosed.</p> <p>b. <input checked="" type="checkbox"/> Please charge by Deposit Account No. <u>23/2825</u> In the amount of \$ <u>1242.00</u> To cover the above fees. A duplicate copy of this sheet is enclosed.</p> <p>c. <input checked="" type="checkbox"/> The commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 23/2825. A duplicate of this sheet is enclosed.</p>					
<p>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b) must be filed and granted to restore the application to pending status.</p>					
SEND ALL CORRESPONDENCE TO			SIGNATURE		
John R. Van Amsterdam WOLF, GREENFIELD & SACKS, P.C. 600 Atlantic Avenue Boston, Massachusetts 02210			 _____ NAME John R. Van Amsterdam _____ 40,212 REGISTRATION NO		

Attorney's Docket No: K0448/7007

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : TANIDA et al.
Int'l Application No. : PCT/JP99/02546
Int'l Filing Date : 17 May 1999
For : SOLID PREPARATIONS FOR ORAL ADMINISTRATION OF
GENE-RELATED DRUGS
Examiner : Unknown
Art Unit : Unknown

Box PCT
Commissioner for Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Sir:

Please amend the application as follows, prior to the calculation of the fees.

In the claims:

Please amend the claims as follows:

1.(amended) A solid preparation with a coating around the core containing a gene-related drug for oral administration with [relesablity] releasability in lower digestive tracts, wherein the coating, not disintegrating in small intestines and has a double-coated structure of an inner layer comprising a cationic copolymer and an outer layer comprising an anionic copolymer.

5.(amended) The solid preparation for oral administration according to claim[s] 2,] 3 [or 4] wherein the mixed ratio of the gene-related drug and the binder is 1:0.2-1:5 or the mixed ratio of the gene-related drug, the binder and the excipient is 1:0.2:0.01-1:5:1.

6.(amended) The solid preparation for oral administration according to claim[s] 4 [or 5] wherein the mixed ratio of the saccharide contained in the core containing the gene-related drug is in the range of 20-60 wt.%.

7.(amended) The solid preparation for oral administration according to claim[s] 4[, 5 or 6] wherein the disintegrator contained in the core containing the gene-related drug is in the range of 2-15 wt.%.

8.(amended) The solid preparation for oral administration according to [any of] claim[s] 4[-7] wherein the disintegrator is mixed for the production in the ratio of 1:0.05-1:10 against the content of the gene-related drug.

9.(amended) The solid preparation for oral administration according to [any of] claim[s] 3[-8] wherein the excipient contained in the core containing the gene-related drug is in the range of 0.1-15 wt.%.

10.(amended) The solid preparation for oral administration according to [any of] claim[s] 1[-9] wherein the gene-related drug contained in the core containing the gene-related drug is in the range of 0.1-50 wt.%.

11.(amended) The solid preparation for oral administration according to [any of] claim[s] 2[-10] wherein the binder contained in the core containing the gene-related drug is in the range of 5-40 wt.%.

12.(amended) The solid preparation for oral administration according to [any of] claim[s] 4[-11] wherein the disintegrators are crospovidone, alpha starch, sodium carboxymethyl starch, carmellose, calcium carmellose, sodium carmellose, agar powder, sodium croscarmellose, crystalline cellulose, low substituted hydroxypropyl cellulose, starch, dextrin, hydroxyethylmethyl cellulose, hydroxypropylmethyl cellulose, polyvinylpyrrolidone, macrogol and mannitol.

13.(amended) The solid preparation for oral administration according to [any of] claim[s] 4[-12] wherein the saccharides are monosaccharides and disaccharides such as lactose, fructose, sucrose, glucose xylitol, maltose, mannitol and sorbitol, or polysaccharides and derivatives

thereof such as cellulose, crystalline cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, ethyl cellulose, starch, dextrin, dextran, pectin and pullulan.

14.(amended) The solid preparation for oral administration according to [any of] claim[s] 3[-13] wherein the excipients are light anhydrous silicic acid, ethyl cellulose, carmellose, agar, magnesium aluminosilicate, calcium silicate, magnesium silicate, cyclodextrin, starch, synthetic aluminum silicate, synthetic hydrotalcite, titanium oxide, zinc oxide, magnesium oxide, alumina magnesium hydroxide, magnesium stearate, calcium stearate, aluminum silicate, talc, crystalline cellulose and lactose.

15.(amended) The solid preparation for oral administration according to [any of] claim[s] [3-13] 1 wherein the gene-related drugs are DNA or RNA, or modified compounds thereof, or compounds thereof conjugated or bound to a carrier.

16.(amended) The solid preparation for oral administration according to [any of] claim[s] 2[-15] wherein the binders are crystalline cellulose, gum arabic, sodium alginate, ethyl cellulose, agar, carboxyvinyl polymer, carmellose, gelatin, low substituted hydroxypropyl cellulose, starch, dextrin, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, pectin, polyvinylpyrrolidone, macrogol and methyl cellulose.

18.(amended) The solid preparation for oral administration according to [any of] claim[s] 1[-14 and 16] wherein the gene-related drugs are one or more drugs selected from the group comprising a nucleic acid, oligonucleotide, antisense, triple helix forming oligonucleotide (TFO), ribozyme, decoy, plasmid, cosmid, P1 phage, YAC (yeast artificial chromosome), chromosome, aptamer and phage.

Remarks

Applicants have amended the claims to eliminate improper multiple dependencies and to clarify the claim language. No new matter has been added.

Respectfully submitted,

By: John R. Van Amsterdam
John R. Van Amsterdam, Reg No. 40,212
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, MA 02210
Telephone (617) 720-3500

Dated: November 20, 2000
Docket No. K0448/7007
Express Mail Label No. EL310414345US

[illegible]

Specification

Title of the Invention

Solid preparations for oral administration of gene-related
drugs

5

TECHNICAL FIELD

The invention relates to a solid preparation for oral
administration of gene-related drugs.

A variety of gene-related drugs have been developed as useful
pharmaceuticals, though in the case of producing them as a solid
preparation for oral administration, there are problems such
as that worsened fluidity of mixed powder due to wettability
of a gene-related drug and viscosity after its moisture
absorption causing a compressing problem, in the case of increase
of the mixed amount, production of tablets with good
disintegration becomes difficult, and, in addition that it is
very difficult to keep stability of a gene-related drug during
a production process. Furthermore, even if a solid preparation
for oral administration can be produced, a gene-related drug
is easily decomposed in digestive tracts due to the unusually
high instability in it, and soon, therefore, it has been generally
considered difficult to develop a solid preparation appropriate
for oral administration.

BACKGROUND ART

On the other hand, in the development of a general solid

preparation for oral administration, recently various attempts have been made to make a drug which easily loses its due to decomposition in small intestines to be absorbed in large intestines in which the enzyme activity of protein decomposition is remarkably low by delivering it to the organ. Illustrative of such examples are oral preparations by the inventors (International application WO, 94/10983, A) mainly for drugs of protein or polypeptide nature having a high specificity toward lower digestive tracts such as large intestines. However, as to a gene-related drug, a solid preparation for oral administration which is practical and effective has not been developed yet owing to the above reasons.

SUMMARY OF THE INVENTION

Consequently, the problem of the invention is to solve problems in the prior art described above in a gene-related drug and to provide a solid preparation for oral administration which is practical and effective. More specifically, it is to provide a solid preparation for oral administration of a gene-related drug in which compressing preparation is easy, preparation processes are stable, and it is effectively absorbed in the digestive tracts.

The inventors made extensive researches to solve the above problems and found out that the decomposition activity for a gene-related drug, as for drugs of peptide nature is remarkably low in large intestines compared with small intestines, and as

the result of continuing further research based on such evidence the inventors accomplished the invention.

Namely, the invention relates to a solid preparation with a coating around the core containing a gene-related drug for oral administration with releasability in lower digestive tracts in small intestines is applied.

The invention also relates to a solid preparation for oral administration in which the core is formed by compressing mixed powder of a gene-related drug and additives appropriately containing a binder, a saccharide, a disintegrator, an excipient or the like, and its outside is coated with an inner layer comprising a cationic copolymer and with an outer layer comprising an anionic copolymer.

Further, the invention comprises the following embodiments.

The above solid preparation for oral administration wherein the mixed ratio of a gene-related drug and a binder is 1:0.2-1:5 or the mixed ratio of a gene-related drug, a binder and an excipient is 1:0.2:0.01-1:5:1.

The above solid preparation for oral administration wherein the mixed ratio of a saccharide contained in the core containing a gene-related drug is in the range of 20-60 wt.%.

The above solid preparation for oral administration wherein a disintegrator contained in the core containing a gene-related drug is in the range of 2-15 wt.%.

The above solid preparation for oral administration,

characterized in that a disintegrator is mixed in the ratio of 1:0.05-1:10 against the mixed amount of a gene-related drug and produced.

The above solid preparation for oral administration wherein an excipient contained in the core containing a gene-related drug is in the range of 0.1-15 wt.%.

The above solid preparation for oral administration wherein a gene-related drug contained in the core of the gene-related drug is in the range of 0.1-50 wt.%.

The above solid preparation for oral administration wherein a binder contained in the core containing a gene-related drug is in the range of 5-40 wt.%.

The above solid preparations for oral administration wherein the disintegrators are crospovidone, alpha starch, sodium carboxymethyl starch, carmellose, calcium carmellose, sodium carmellose, agar powder, sodium croscarmellose, crystalline cellulose, low substituted hydroxypropyl cellulose, starch, dextrin, hydroxyethylmethyl cellulose, hydroxypropyl starch, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, polyvinylpyrrolidone, macrogol and mannitol.

The above solid preparations for oral administration wherein the saccharide are monosaccharides and disaccharides such as lactose, fructose, sucrose, glucose, xylitol, maltose, mannitol and sorbitol, or polysaccharides and derivatives thereof such as cellulose, crystalline cellulose, hydroxypropyl

cellulose, hydroxyethylmethyl cellulose, ethyl cellulose, starch, dextrin, dextran, pectin and pullulan.

The above solid preparations for oral administration wherein the excipients are light anhydrous silicic acid, ethyl cellulose, carmelose, agar, magnesium aluminosilicate, calcium silicate, magnesium silicate, cyclodextrin, starch, synthetic aluminum silicate, synthetic hydrotalcite, titanium oxide, zinc oxide, magnesium oxide, alumina magnesium hydroxide, magnesium stearate, calcium stearate, aluminum silicate, talc, crystalline cellulose and lactose.

The above solid preparations for oral administration wherein the gene-related drugs are DNA, RNA and modified compounds thereof, and compounds thereof conjugated or bound to a carrier.

The above solid preparations for oral administration wherein the binders are crystalline cellulose, gum arabic, sodium alginate, ethyl cellulose, agar, carboxyvinyl polymer, carmelose, gelatin, low substituted hydroxypropyl cellulose, starch, dextrin, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, pectin, polyvinylpyrrolidone, macrogol and methyl cellulose.

The above solid preparations for oral administration wherein the carriers comprise a cationic polymer, cationic lipid, virus vector and phage.

The above solid preparations for oral administration

wherein the gene-related drugs comprise a nucleic acid,
oligonucleotide, antisense, triple helix forming
oligonucleotide (TFO), ribozyme, decoy, plasmid, cosmid, P1 phage,
YAC (yeast artificial chromosome), chromosome, aptamer and
phage.

Thus, the above problems were solved once for all by the
solid preparations for oral administration of the invention.

[Detailed Description of the Preferred Embodiments]

In the invention, illustrative of available gene-related
drugs are DNA, RNA and modified compounds thereof, and compounds
thereof conjugated or bound to a carrier, nucleic acid,
oligonucleotide, antisense, triple helix forming
oligonucleotide (TFO), ribozyme, decoy and plasmid.
Illustrative of the carriers used are cationic polymer, cationic
lipid, virus vector and phage.

Specifically, in the case of aiming at the colitis therapy
as a topical therapeutic use are illustrated suppressive type
gene pharmaceuticals such as TNF- α (Tumor necrosis factor α),
ICAM-1 (Intercellular adhesion molecule-1), COX-2
(Cyclooxygenase-2), IL-1 (Interleukin-1), IL-6 (Interleukin-6)
and IL-8 (Interleukin-8), or expression type gene
pharmaceuticals such as IL-2 (Interleukin-2) and IL-10
(Interleukin-10). In the case of aiming at the colon cancer
are illustrated suppressive type gene pharmaceuticals such as
ICAM-1, COX-2 and TGF- β (Transforming growth factor β), or

expression type gene pharmaceuticals such as INF- γ
(Interferon- γ), TNF- α , APC (Adenomatous Polyposis Coli), p53,
MCC (Mutated in Cololateral Carcinoma) and DCC (deleted on
colorectal carcinomas). Further, in the case of aiming at the
5 systemic diseases are illustrated suppressive type gene
pharmaceuticals such as TNF- α , ICAM-1, COX-2, IL-1, IL-6, HIV
(human immunodeficiency virus), bile acid transporter and each
transporter of the small intestine, or expression type gene
pharmaceuticals such as INF- γ , TNF- α , G-CSF (Granulocyte
10 colony-stimulating facor), GM-CSF (Granulocyte macrophage
colony-stimulating facor), glucose transporter, LHRH
(Luteonizing hormone-releasing hormone) and calcitonin.

Also, in the invention, as to the above additives, an
appropriate material and an appropriate mixed amount are
15 selected by considering the fluidity of mixed powder, the
disintegration of tablets, and the stability at the time of
production.

In the following, the embodiments of the preparations are
explained according to the method of production, the invention
20 however, is not limited in any way by these.

First, the gene-related drug and the binder, or the
gene-related drug, the binder and the excipient are mixed and
ground using an appropriate micro-smasher such as an agate mortar,
jet mill, pin mill or ball mill.

Here, illustrative of the available binders are crystalline cellulose, gum arabic, sodium alginate, ethyl cellulose, agar, carboxyvinyl polymer, carmellose, gelatin, low substituted hydroxypropyl cellulose (trade name; L-HPC, Shinnetsu Kagaku Kogyo Co., Ltd.), starch, dextrin, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, pectin, polyvinylpyrrolidone, macrogol and methyl cellulose. Preferably crystalline cellulose is used.

Further, illustrative of the excipients are light anhydrous silicic acid, ethyl cellulose, carmellose, agar, magnesium silicate aluminate, calcium silicate, magnesium silicate, cyclodextrin, starch, synthetic aluminum silicate, synthetic hydrotalcite, titanium oxide, zinc oxide, magnesium oxide, alumina magnesium hydroxide (aluminum magnesium hydroxide), magnesium stearate, calcium stearate, aluminum silicate, talc, crystalline cellulose and lactose. Preferably light anhydrous silicic acid is used.

The mixed ratio of the binder contained in the core containing the gene-related drug is 5-40 wt.%, preferably 10-25 wt.%, likewise the mixed ratio of the excipient is 0.1-15 wt.%, preferably 1-5 wt.%, furthermore likewise the mixed ratio of the gene-related drug is 0.1-50 wt.%, preferably 5-30 wt.%.

On the other hand, the mixed ratio of the gene-related drug and the binder is in a preferable range for the fluidity of the mixed powder, the disintegration of tablets and the

compressibility, specifically 1:0.2-1:5, preferably 1:0.5-1:2. From the same standpoint, the mixed ratio of the gene-related drug, the binder and the excipient is 1:0.2:0.01-1:5:1, preferably 1:0.5:0.02-1:2:0.05.

5 Subsequently, the saccharide and the disintegrator is added to the obtained mix-ground product and mixed. Magnesium stearate is added to the mixture, and compressed with an appropriate tablet machine.

10 Here, illustrative of the saccharide are monosaccharides and disaccharides such as lactose, fructose, sucrose, glucose, xylitol, maltose, mannitol and sorbitol, or polysaccharides and derivatives thereof such as cellulose, crystalline cellulose, hydroxypropyl cellulose, hydroxyethylmethyl cellulose, ethyl cellulose, starch, dextrin, dextran, pectin and pullulan. Preferably lactose is used.

15 Here, illustrative of the disintegrators are crospovidone, alpha starch, sodium carboxymethyl starch, carmellose, calcium carmellose, sodium carmellose, agar powder, sodium croscarmellose, crystalline cellulose, low substituted
20 hydroxypropyl cellulose (trade name; L-HPC, Shinnetsu Kagaku Kogyo Co., Ltd.), starch, dextrin, hydroxyethylmethyl cellulose, hydroxypropyl starch, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, polyvinylpyrrolidone, macrogol and mannitol. Preferably crospovidone is used.

25 The mixed ratio of the excipient contained in the core

containing the gene-related drug is 2-25 wt.%, preferably 5-15 wt.%, likewise the mixed ratio of the sugar is 20-60 wt.%, preferably 30-50 wt.%. The mixed ratio of the disintegrator against the mixed amount of the gene-related drug is in the range preferable for having a suitable disintegration in order to be delivered to the target site in the digestive tracts and for the compressibility, specifically in the ratio of 1:0.05-1:10, preferably 1:0.1-1:5. The mixed ratio of cross-povidone as the disintegrator is in the range of 2.5-20 wt.%, preferably 5-15 wt.%.

Subsequently, the surface of the obtained uncoated tablet (core) is coated with the cationic copolymer and further with the anionic copolymer. As to the coating, coating solution is continuously applied by spraying under the condition that said core is kept at 30-50°C. The weight increase due to the cationic copolymer and the anionic copolymer is 5-15 wt.% based on the weight of the uncoated tablet, preferably 6-8 wt.%.

The cationic copolymer used as the inner layer has properties to be soluble or swelling at pH of 6.0 or below. Famous polymers include aminoalkyl methacrylate copolymer, a general name [copolymer comprising methyl methacrylate, butyl methacrylate and dimethylaminomethyl methacrylate, trade name: Eudragit E, manufactured by Röhm Co., Ltd.] or polyvinyl acetal diethylaminoacetate (trade name: AEA, manufactured by Sankyo Co., Ltd.). This polymer layer (inner layer) is formed by the

use of membrane having the thickness of 10-300 μm and 1-40 wt.% of said solid drug weight, and regulated so as to release the active substance from said solid drug quickly when the pH condition of 6.0 or below continues. As for this inner layer, a suitable plastisizer is preferably used to obtain smooth coating membrane. The plastisizer includes triacetin, citric acid ester and polyethylene glycol. Also, the binding inhibitor includes talc, titanium oxide, calcium phosphate, hydrophobic light anhydrous silicic acid, etc.

The anionic copolymer used as the outer layer has a property to be easily soluble at pH of 5.5 or above. Famous polymers include methacrylic acid copolymer L, a general name, (copolymer comprising methacrylic acid and methyl methacrylate, trade name: Eudragit L100, manufactured by Röhm Co., Ltd.), methacrylic acid copolymer S (copolymer comprising methacrylic acid and methyl methacrylate, trade name: Eudragit S, manufactured by Röhm Co., Ltd.), hydroxypropylmethyl cellulose acetate succinate, hydroxypropylmethyl cellulose phthalate, etc. Said polymer is used in 1-40 wt.% of said solid drug.

According to the preparations, the gene-related drug can be delivered to the lower digestive tracts which can absorb it maintaining its activity stable, in particular to large intestines specifically, and the preparations disintegrate quickly at the same time of their delivery, therefore, the gene-related drug, which is a pharmacologically active substance,

is released without loss of its activity. Further, at the time of production, the fluidity of powder is not destroyed to make stable compressing of tablets possible, and furthermore the stability of the gene-related drug can sufficiently be guaranteed in the time of production.

Example

In the following, the invention is explained more concretely by the examples. The invention is not limited to these examples in any way.

Example 1

<Preparation of TNF α antisense>

The antisense (thio DNA) of TNF α with the sequence 5'-ATC Atg CTT TCT gTg CTC AT-3' was synthesized using the reagents shown in the following Table 1 on a nucleotide synthesis machine of DNA Synthesizer Oligo Pilot II (Pharmacia).

Table 1

Reagent	Valid term	Manufacturer	Lot No.	Amount used (ml)
Acetonitril	96.09.16	Pharmacia Biotech.	55383	9130
Detritylation	96.09.17	Pharmacia Biotech.	53968	7125
0.1MT-amidite	96.09.02	Pharmacia Biotech.	5111736061	70
0.1MA*-amidite	96.09.02	Pharmacia Biotech.	5071730051	27
0.1MC*-amidite	96.09.02	Pharmacia Biotech.	5081732061	44
0.1MG*-amidite	96.09.02	Pharmacia Biotech.	5111734061	27
Capping A	96.09.16	Pharmacia Biotech.	55371	233
Capping B	96.09.16	P Pharmacia Biotech.	55914	233
Oxidation	96.09.16	Pharmacia Biotech.	30465	4
Beaucage	96.09.16	Pharmacia Biotech.	6049798021	460
Tetrazole	96.09.16	Pharmacia Biotech.	6042875041	621

The crude oligonucleotide obtained was subsequently separated and purified under the following conditions on FPLC System manufactured by Pharmacia. Finally, its purity was checked using HPLC to confirm that the TNF α antisense (thio DNA) of 100% purity was obtained.

<Preparation of TNF α antisense tablets>

The tablets containing the TNF α antisense produced by the above procedures were produced according to the following

formulation in Table 2-1 and Table 2-2. First, the TNF α antisense and light anhydrous silicic acid, or the TNF α antisense, crystalline cellulose and light anhydrous silicic acid were mixed and ground using a grinding machine, subsequently added with lactose and cross-povidone, mixed, finally added with magnesium stearate, and mixed. The mixture was compressed using a tablet machine to produce tablets having the diameter of 7 mm and the weight of 200 mg.

Table 2-1

	(1)	(2)	(3)	(4)
TNF α antisense	25	25	25	25
Crystalline cellulose	21	20	20	20
Lactose	43	43	48	50.5
crospovidone	10	10	5	2.5
Light anhydrous silicic acid	0	1	1	1
Magnesium stearate	1	1	1	1

* Each figure in Table represents parts by weight

Table 2-2

	(5)	(6)	(7)	(8)
TNF α antisense	25	25	25	25
Crystalline cellulose	21	41	11	5
Lactose	33	23	53	59
crospovidone	20	10	10	10
Magnesium stearate	1	1	1	1

* Each figure in Table represents parts by weight

The following coating was carried out on said cores obtained.

Eudragit E	7 pt. by wt.
Ethanol	70 pt. by wt.
Water	19.5 pt. by wt.
Talc	3.5 pt. by wt.

5 As to the inner layer, the above solution was continuously applied by spraying under the condition that said cores were kept at 50°C. The weight increase of said core was 14 mg per tablet. After spraying, said cores were dried and further applied with the following solution.

Eudragit S	7.0 pt. by wt.
Ethanol	70.0 pt. by wt.
Water	18.8 pt. by wt.
Talc	3.5 pt. by wt.
Polyethylene glycol 600	0.7 pt. by wt.

15 As to the outer layer, the above solution was continuously applied by spraying under the condition in which said cores were kept at 50°C. The weight increase of said core was 14 mg per tablet.

Comparative Example 1

20 <Preparation of TNF α antisense tablets>

The tablets containing the TNF α antisense were produced according to the following formulation. First, the TNF α antisense, crystalline cellulose and lactose were mixed in a vinyl bag. The mixture was added finally with magnesium stearate,

mixed and compressed using a tablet machine to produce tablets having the diameter of 7 mm and the weight of 200 mg.

TNF α antisense 26.5 pt. by wt.

Crystalline cellulose 21 pt. by wt.

5 Lactose 51.5 pt. by wt.

Magnesium stearate 1 pt. by wt.

The following coating was carried out on said cores obtained.

Eudragit E 7 pt. by wt.

Ethanol 70 pt. by wt.

10 Water 19.5 pt. by wt.

Talc 3.5 pt. by wt.

As to the inner layer, the above solution was continuously applied by spraying under the condition in which said cores were kept at 50°C. The weight increase of said core was 14 mg per tablet. After spraying, said cores were dried and further applied with the following solution.

Eudragit S 7.0 pt. by wt.

Ethanol 70.0 pt. by wt.

Water 18.8 pt. by wt.

20 Talc 3.5 pt. by wt.

Polyethylene glycol 600 0.7 pt. by wt.

As to the outer layer, the above solution was continuously applied by spraying under the condition in which said cores were kept at 50°C. The weight increase of said core was 14 mg per tablet.

25

Comparative Example 2

<Preparation of TNF α antisense tablets>

The tablets containing the TNF α antisense were produced according to the following formulation. First, the TNF α antisense, crystalline cellulose, lactose and crospovidone were mixed in a vinyl bag. The mixture was added finally with magnesium stearate, mixed and compressed using a tablet machine to produce tablets having the diameter of 7 mm and the weight of 200 mg.

TNF α antisense	26.5 pt. by wt.
Crystalline cellulose	21 pt. by wt.
Lactose	41.5 pt. by wt.
Crospovidone	10 pt. by wt.
Magnesium stearate	1 pt. by wt.

The following coating was carried out on said cores obtained.

Eudragit E	7 pt. by wt.
Ethanol	70 pt. by wt.
Water	19.5 pt. by wt.
Talc	3.5 pt. by wt.

As to the inner layer, the above solution was continuously applied by spraying under the condition in which said cores were kept at 50°C. The weight increase of said core was 14 mg per tablet. After spraying, said cores were dried and further applied with the following solution.

Eudragit S	7.0 pt. by wt.
------------	----------------

Ethanol	70.0 pt. by wt.
Water	18.8 pt. by wt.
Talc	3.5 pt. by wt.
Polyethylene glycol 600	0.7 pt. by wt.

5 As to the outer layer, the above solution was continuously applied by spraying under the condition in which said cores were kept at 50°C. The weight increase of said core was 14 mg per tablet.

Test Example 1

10 The evaluation was made on the disintegration and the content uniformity of the tablets prepared in the Example 1 and the Comparative Examples 1 and 2, and on the fluidity of mixed powders in the production processes and the compressibility of powders. The evaluation was made on the fluidity of the powders by the deviation of the weight of uncoated tablets, on the compressibility by the hardness of uncoated tablets prepared at the compressing pressure of 2.0 tons or less, the adhesion of powders to the mortar and the mallet at the time of compressing or the cracking after capping, sticking, lamination and coating of tablets.

20 As to the content uniformity test, the test was carried out according to the test method described in the 13th Japanese Pharmacopoeia using 10 tablets. As to the disintegration test, the test was carried out under the following conditions using disintegrating machine of Japanese Pharmacopoeia.

25

Test method for disintegration test:

About 1L of buffer solution of pH 7.5 was added into a wall-thick beaker and placed in the water bath of a disintegration test machine, whereby water temperature was set at about 39°C.

5 In each of six auxiliary cylinders installed in a basket one tablet was inserted, further an auxiliary plate was inserted on the tablet, and the basket was mounted to the hanging rod. After confirming that the water temperature of the buffer solution of pH 7.5 in the wall-thick beaker was kept at about 10 37°C, the test was started. The basket was moved up and down in the buffer solution of pH 7.5 for 4 hours and subsequently moved up and down in the buffer solution of pH 5.5. The time spend from the time of the transfer to the buffer solution of pH 5.5 until the tablet's disintegration was measured and 15 recorded. The tablet was judged to have disintegrated when the powders inside the coating membrane disappeared and a part of the auxiliary plate touched the basket.

1. Preparation of buffer solution

Buffer solution of pH 7.5:

20 Sodium chloride 63.09 g, sodium dihydrogenphosphate dihydrate 0.936 g and disodium hydrogenphosphate dodecahydrate 13.053 g were measured respectively, dissolved with addition of purified water and made to 6 L after being adjusted to pH 7.5.

25 Buffer solution of pH 5.5:

Sodium chloride 63.09 g, 3.5M aq. acetic acid solution 3.5 mL and 2M sodium acetate solution 60 mL were measured respectively, dissolved with addition of purified water and made to 6 L after being adjusted to pH 5.5.

5 The test results are shown in Table 3;

1. Mixing effect of a disintegrator (crospovidone):

Comparing the disintegration of the preparation of the comparative example 1 prepared without mixing crospovidone with that of the preparation of the Example 1-(1) mixed with crospovidone, the disintegration of the preparation of the Comparative Example 1 was extremely bad; on the contrary the preparation of the Example 1-(1) showed good disintegration.

2. Effect of mixed and grinding:

Comparing the fluidity of the mixed powders before compressing in the preparation of the Example 1-(1) in which the mixed grinding was made in the production process with that in the preparation of the Comparative Example 2 of the same formulation in which the mixed grinding was not made, the fluidity was extremely low in the Comparative Example 2 in which the mixed grinding was not made; on the contrary the Example 1-(1) showed a good fluidity.

3. Examination of the mixed ratio of a disintegrator (crospovidone):

Comparing the disintegration of the tablets of the Examples 1-(1), (2), (3), (4) and (5) formulated with mixed amounts of

crospovidone 5-10 wt.%, in the mixed amount of less than 10 wt.%, the disintegration was in the range of acceptance, but it was a little bad; that of the mixed amount of 10 wt.% showed the most suitable disintegration time. Further, in the mixed amount of 20 wt.% (the Example 1-(5)) the compressibility was bad, and there was a tendency that disintegration was conversely too speedy.

4. Examination of the mixed ratio of a binder (crystalline cellulose):

Comparing the fluidity and the compressibility of the tablets of the examples 1-(1), (6), (7), and (8) formulated with a mixed amount of crystalline cellulose 5-41 wt.%, in 5 wt.% the fluidity was a little bad and there was also a problem in compressibility. That showing the most suitable fluidity and compressibility was the formulation of 20 wt.% (Example 1-(1)). In the formulation (tablet (6)) in which the mixed amount of crystalline cellulose was increased to 40 wt.%, there was a tendency that the compressibility got worse.

Table 3

	Tablet No.	Fluidity	Compressibility	Disintegration	Content uniformity test result
Example 1	(1)	O	O	O	O
	(2)	O	O	△	O
	(3)	O	O	△	O
	(4)	O	O	X	O
	(5)	O	X	X	-
	(6)	O	△	O	O
	(7)	△	△	-	-
	(8)	X	X	-	-
Comparative Example 1		X	X	X	X
Comparative Example 2		X	X	△	X

*O: Good,

△: Within the range of acceptance, but a little problematic,

X: Problematic,

-: Not evaluated

CLAIM

1. (as amended) A solid preparation with a coating around the core containing a gene-related drug for oral administration with releasability in lower digestive tracts, wherein the coating, not disintegrating in small intestines and has a double-coated structure of an inner layer comprising a cationic copolymer and an outer layer comprising an anionic copolymer.

2. (as amended) The solid preparation for oral administration according to claim 1 wherein the core containing the gene-related drug contains a binder as an additive.

3. (as amended) The solid preparation for oral administration according to claim 2 wherein the core containing the gene-related drug further contains an excipient as an additive.

4. (as amended) The solid preparation for oral administration according to claims 2 or 3 wherein the gene-related drug further contains one or both of a disintegrator and a saccharide as additives.

5. (as amended) The solid preparation for oral administration according to claims 2, 3 or 4 wherein the mixed ratio of the gene-related drug and the binder is 1:0.2-1:5 or the mixed ratio of the gene-related drug, the binder and the excipient is 1:0.2:0.01-1:5:1.

6. (as amended) The solid preparation for oral administration according to claims 4 or 5 wherein the mixed ratio of the saccharide contained in the core containing the gene-related drug is in

the range of 20-60 wt.%.

7. (as amended) The solid preparation for oral administration according to claims 4, 5 or 6 wherein the disintegrator contained in the core containing the gene-related drug is in the range of 2-15 wt.%.

8. (as amended) The solid preparation for oral administration according to any of claims 4-7 wherein the disintegrator is mixed for the production in the ratio of 1:0.05-1:10 against the content of the gene-related drug.

9. (as amended) The solid preparation for oral administration according to any of claims 3-8 wherein the excipient contained in the core containing the gene-related drug is in the range of 0.1-15 wt.%.

10. (as amended) The solid preparation for oral administration according to any of claims 1-9 wherein the gene-related drug contained in the core containing the gene-related drug is in the range of 0.1-50 wt.%.

11. (as amended) The solid preparation for oral administration according to any of claims 2-10 wherein the binder contained in the core containing the gene-related drug is in the range of 5-40 wt.%.

12. (as amended) The solid preparation for oral administration according to any of claims 4-11 wherein the disintegrators are crospovidone, alpha starch, sodium carboxymethyl starch, carmellose, calcium carmellose, sodium

carmellose, agar powder, sodium croscarmellose, crystalline cellulose, low substituted hydroxypropyl cellulose, starch, dextrin, hydroxyethylmethyl cellulose, hydroxypropyl starch, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, polyvinylpyrrolidone, macrogol and mannitol.

13. (as amended) The solid preparation for oral administration according to any of claims 4-12 wherein the saccharides are monosaccharides and disaccharides such as lactose, fructose, sucrose, glucose, xylitol, maltose, mannitol and sorbitol, or polysaccharides and derivatives thereof such as cellulose, crystalline cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, ethyl cellulose, starch, dextrin, dextran, pectin and pullulan.

14. (as amended) The solid preparation for oral administration according to any of claims 3-13 wherein the excipients are light anhydrous silicic acid, ethyl cellulose, carmellose, agar, magnesium aluminosilicate, calcium silicate, magnesium silicate, cyclodextrin, starch, synthetic aluminum silicate, synthetic hydrotalcite, titanium oxide, zinc oxide, magnesium oxide, alumina magnesium hydroxide, magnesium stearate, calcium stearate, aluminum silicate, talc, crystalline cellulose and lactose.

15. (as amended) The solid preparation for oral administration according to any of claims 3-13 wherein the gene-related drugs are DNA or RNA, or modified compounds thereof,

or compounds thereof conjugated or bound to a carrier.

16. (as amended) The solid preparation for oral administration according to any of claims 2-15 wherein the binders are crystalline cellulose, gum arabic, sodium alginate, ethyl cellulose, agar, carboxyvinyl polymer, carmellose, gelatin, low substituted hydroxypropyl cellulose, starch, dextrin, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, pectin, polyvinylpyrrolidone, macrogol and methyl cellulose.

17. (as amended) The solid preparation for oral administration according to claim 15 wherein the carriers comprising a cationic polymer, cationic lipid, virus vector and phage.

18. (as added) The solid preparation for oral administration according to any of claims 1-14 and 16 wherein the gene-related drugs are one or more drugs selected from the group comprising a nucleic acid, oligonucleotide, antisense, triple helix forming oligonucleotide (TFO), ribozyme, decoy, plasmid, cosmid, P1 phage, YAC (yeast artificial chromosome), chromosome, aptamer and phage.

ABSTRACT

The invention provides solid preparations for oral administration of gene-related drugs comprising a core containing the gene-related drug with a coating which does not disintegrated in small intestines, wherein said preparations can be easily tabletted, remain stable during the preparation process and said drug can be efficiently absorbed in digestive tracts.

DECLARATION FOR PATENT APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am an original, first and joint inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled:

SOLID PREPARATIONS FOR ORAL ADMINISTRATION OF GENE-RELATED DRUGS

the specification of which is attached hereto unless the following is checked:

[X] was filed on May 17, 1999, as PCT International Application No. PCT/JP99/02546, bearing attorney docket No. K0448/.

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate, or section 365(a) of any PCT International application designating at least one country other than the United States listed below and have also identified below any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed:

Prior Foreign PCT International Application(s) and any priority claims under 35 U.S.C. §§119 and 365(a),(b):

Priority
Claimed

10-153912
(Number)

Japan
(Country-if PCT, so indicate)

19/05/98
(DD/MM/YY Filed)

☒ YES ☐ NO

(Number)

(Country-if PCT, so indicate)

(DD/MM/YY Filed)

☐ YES ☐ NO

(Number)

(Country-if PCT, so indicate)

(DD/MM/YY Filed)

☐ YES ☐ NO

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below:

(Application Number)

(filing date)

(Application Number)

(filing date)

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s), or §365(c) of any PCT International application(s) designating the United States of America listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

(Application No.)	(filing date)	(status-patented, pending, abandoned)
(Application No.)	(filing date)	(status-patented, pending, abandoned)

PCT International Applications designating the United States:

(PCT Appl. No.)	(U.S. Ser. No.)	(PCT filing date)	(status-patented, pending, abandoned)
-----------------	-----------------	-------------------	---------------------------------------

I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Robert M. Abrahamsen	<u>40,886</u>	Jason M. Honeyman	<u>31,624</u>	Stanley Sacks	<u>19,900</u>
John N. Anastasi	<u>37,765</u>	Robert E. Hunt	<u>39,231</u>	Christopher S. Schultz	<u>37,929</u>
Gary S. Engelson	<u>35,128</u>	Ronald J. Kransdorf	<u>20,004</u>	Alan B. Sherr	<u>42,147</u>
Neil P. Ferraro	<u>39,188</u>	Peter C. Lando	<u>34,654</u>	Robert A. Skrivaneck, Jr.	<u>41,316</u>
Thomas G. Field	<u>45,596</u>	Helen C. Lockhart	<u>39,248</u>	Paul D. Sorkin	<u>39,039</u>
Stephen R. Finch	<u>42,534</u>	Matthew B. Lowrie	<u>38,228</u>	Alan W. Steele	<u>45,128</u>
Edward R. Gates	<u>31,616</u>	William R. McClellan	<u>29,409</u>	Mark Steinberg	<u>40,828</u>
Richard F. Giunta	<u>36,149</u>	Daniel P. McLoughlin	<u>46,066</u>	Joseph Teja, Jr.	<u>45,157</u>
Peter J. Gordon	<u>35,164</u>	James H. Morris	<u>34,681</u>	John R. Van Amsterdam	<u>40,212</u>
John C. Gorecki	<u>38,471</u>	M. Lawrence Oliverio	<u>30,915</u>	Michael G. Verga	<u>39,410</u>
William G. Gosz	<u>27,787</u>	Timothy J. Oyer	<u>36,628</u>	Robert H. Walat	<u>46,324</u>
Lawrence M. Green	<u>29,384</u>	Edward F. Perlman	<u>28,105</u>	Lisa E. Winsor	<u>44,405</u>
George L. Greenfield	<u>17,756</u>	Michael J. Pomianek	<u>46,190</u>	David Wolf	<u>17,528</u>
James M. Hanifin, Jr.	<u>39,213</u>	Elizabeth R. Plumer	<u>36,637</u>	Douglas R. Wolf	<u>36,971</u>
Therese A. Hendricks	<u>30,389</u>	Randy J. Pritzker	<u>35,986</u>	Ivan D. Zitkovsky	<u>37,482</u>
Steven J. Henry	<u>27,900</u>	Robert E. Rigby, Jr.	<u>36,904</u>		
		Edward J. Russavage	<u>43,069</u>		

Address all telephone calls to John R. Van Amsterdam at telephone no. (617) 720-3500. Address all correspondence to:

John R. Van Amsterdam
c/o Wolf, Greenfield & Sacks, P.C.,
Federal Reserve Plaza
600 Atlantic Avenue
Boston, MA 02210-2211

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment,

48 OCT 2000

or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Norifumi Tanida

18th Sep. 2000

1-00
Inventor's signature

Date

Full name first or sole inventor:

Norifumi Tanida

Citizenship:

Japan

Residence:

Ibaraki, Japan JPX

Post Office Address:

c/o HISAMITSU PHARMACEUTICAL CO., INC., Tsukuba
Research Laboratories, 25-11, Kannondai 1-chome, Tsukuba-
shi, Ibaraki 305-0856 JAPAN

Takeshi Goto

18th Sep. 2000

2-00
Inventor's signature

Date

Full name second or joint inventor:

Takeshi Goto

Citizenship:

Japan

Residence:

Ibaraki, Japan JPX

Post Office Address:

c/o HISAMITSU PHARMACEUTICAL CO., INC., Tsukuba
Research Laboratories, 25-11, Kannondai 1-chome, Tsukuba-
shi, Ibaraki 305-0856 JAPAN

Jun Aoki

18th Sep. 2000

3-00
Inventor's signature

Date

Full name third or joint inventor:

Jun Aoki

Citizenship:

Japan

Residence:

Ibaraki, Japan JPX

Post Office Address:

c/o HISAMITSU PHARMACEUTICAL CO., INC., Tsukuba
Research Laboratories, 25-11, Kannondai 1-chome, Tsukuba-
shi, Ibaraki 305-0856 JAPAN